Objectives. +is study evaluated the clinical manifestation of COVID-19 and adverse outcomes in patients with comorbidities
(outcome: death). Methods. A comparative follow-up investigation involving 148 confirmed cases of COVID-19 was performed
for a month (between April and May 2020) at Qaha Hospital to describe the clinical characteristics and outcomes resulting from
comorbidities. Participants were divided into two clusters based on the presence of comorbidities. Group I comprised cases with
comorbidities, and Group II included subjects without comorbidity. Survival distributions were outlined for the group with
comorbidities after the follow-up period. Results. Fever (74.3%), headache (78.4%), cough (78.4%), sore throat (78.4%), fatigue
(78.4%), and shortness of breath (86.5%) were the most prevalent symptoms observed in COVID-19 patients with comorbidities.
Such patients also suffered from acute respiratory distress syndrome (37.8%) and pneumonia three times more than patients
without comorbidities. +e survival distributions were statistically significant (chi-square � 26.06, p ≤ 0.001). Conclusion. Multiple
comorbidities in COVID-19 patients are linked to severe clinical symptoms, disease complications, and critical disease progression.
+e presence of one or more comorbidities worsened the survival rate of patients. |
